Veronica Mullally Muñoz
Veronica Mullally MuñozSenior Partner
New York
vmunoz@oreillyip.com
212 540 0652

Highlights

Veronica is a first-chair trial lawyer. She has over 25 years of experience representing companies from Fortune 500 to start-ups and has broad experience in both bench and jury trials and in the appellate process. Formerly a Partner at Orrick and then at Hogan Lovells, Veronica brings top quality legal skills and experience to the table.  She handles cases involving all types of intellectual property and commercial disputes. She has tried cases involving a wide range of technologies including pharmaceuticals, biologics, siRNA, gene sequencing, transgenic plants, cardiovascular stents, medical devices and mechanical, high-tech, software and electrical products. Veronica also has extensive experience in Hatch Waxman litigation.   Veronica was recognized by Chambers as an internationally ranked life sciences lawyer.

Before attending law school, Veronica was a biochemist and worked in academic research and in industry. She did post-graduate research on the gut hormone secretin and later worked on a leukemia research team at the John Radcliffe hospital in Oxford, UK. She was also a research scientist at Celltech Ltd., U.K., where she helped develop some of the first uses of monoclonal antibodies.

Education

  • The Pace University School of Law, J.D., NY
    • J.D., magna cum laude, May 1996
    • Environmental Law Certificate 1996
    • Honors: Law Trustee Scholarship 1993-1996
  • The Queen’s University of Belfast, N. Ireland
    • B.Sc. (Honors) Biochemistry, (equivalent to U.S. Master’s degree)
    • Honors: Awarded Ph.D. research scholarship

Admitted

  • U.S. Supreme Court
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. Court of Appeals for the Second Circuit
  • U.S. District Court, SDNY
  • U.S. District Court, Connecticut
  • New York State Courts
  • Connecticut State Courts
  • U.S. Patent & Trademark Office

Representative Matters

  • Research Corporation Technologies, Inc. v. Eli Lilly and Company, representing RCT on a breach of license agreement involving Lilly’s use of Pichia expression technology in the manufacture of its flag ship diabetes drugs.  Liability for unpaid royalties on Insulin was won on summary judgment.  The case is expected to be tried to a jury in Tucson, AZ in early 2023.
  • Academy Orthotic & Prosthetic Associates IPA, Inc. et al v. Fitango Health, Inc. et al, case involving breach of contract and theft of software technology.  A favorable settlement was achieved.
  • Broker Genius Inc. v. Seat Scouts LLC et al., a breach of contract and unfair competition action where a Preliminary Injunction was granted.  A multi-million dollar jury verdict and Permanent Injunction were subsequently won.  Both the verdict and the injunction were successfully defended on appeal.
  • BRIESE LICHTTECHNIK VERTRIEBS GmbH v.Langton a patent infringement case involving photographiclighting technology, a jury verdict was won and successfully defended on appeal.
  • Dow Agro Sciences v. Monsanto, case involving an inventorship dispute regarding an important transgenic plant gene won for Dow Agro Science at a bench trial.
  • Protiva v. SIRNA Therapeutic (a Merck subsidiary), Theft of trade secrets case involving siRNA delivery technology, obtained a preliminary injunction and a favorable settlement for Protiva
  • Syngenta Seeds, Inc. v. Monsanto Co., obtained jury verdict in transgenic plant technology patent infringement case
  • Allergan, Inc. v. Alcon Laboratories, Inc., two successive Hatch Waxman patent infringement cases won on summary judgment and successfully defended on appeal.
  • Cordis v Boston Scientific and Cordis v. Medinol, two multimillion dollar verdicts on patent infringement cases involving cardiac stents and four jury trials on bifurcated liability and damages.
  • Ortho Pharmaceutical Corp. v. Amgen, Inc., arbitration of a contract dispute involving a $3 billion erythropoietic biotherapeutic.